Prognostic Factors on the Graft-versus-Host Disease-Free and Relapse-Free Survival after Adult Allogeneic Hematopoietic Stem Cell Transplantation

Table 3

Prognostic factors for 2-year GRFS after adult allogeneic HSCT.

Factors		Events	%	Univariate analysis			Multivariate analysis
				HR	95% CI	value	HR	95% CI	value
Age at HSCT
35	139	74	53.2	1.452	1.102–1.913	0.008	1.080	0.799–1.459	0.617
35	238	160	67.2
EBMT risk score
2	155	73	47.1	2.165	1.640–2.857	<0.001	1.835	1.354–2.486	<0.001
2	222	161	72.7
Gender
Female	168	89	53.0	1.456	1.118–1.896	0.005	1.348	1.032–1.761	0.028
Male	209	145	69.4
Disease type
Nonmalignant	48	16	33.3	2.495	1.500–4.149	<0.001	1.979	1.178–3.324	0.010
Malignant	329	218	66.3
Disease type
Myeloid	176	117	66.5	0.836	0.647–1.081	0.172
Nonmyeloid	201	117	58.2
Conditioning
Nonmyeloablative	129	75	58.1	1.135	0.863–1.494	0.365
Myeloablative	248	159	64.1
Conditioning
Others	252	150	59.5	1.246	0.953–1.627	0.107
12 Gy TBI based	125	84	67.2
Conditioning
Others	303	179	59.1	1.494	1.104–2.022	0.009	1.115	0.811–1.532	0.503
Fludarabine based	74	55	74.3
Donor type
Matched sibling	181	119	65.7	0.976	0.755–1.261	0.851
Others	196	115	58.7
Type 2 DM
No	362	224	61.9	1.260	0.699–2.375	0.474
Yes	15	10	66.7
Smoking history
No	353	216	61.2	1.415	0.903–2.364	0.122
Yes	24	18	75.0
Posttransplant CMV reactivation
No	187	107	57.2	1.349	1.042–1.746	0.023	1.170	0.899–1.523	0.242
Yes	190	127	66.8
PTLD
No	362	228	62.9	1.463	0.651–3.292	0.357
Yes	15	6	40.0

CI: confidence interval; HR: hazard ratio; EBMT: European Group for Blood and Marrow Transplantation; HSCT: hematopoietic stem cell transplantation; PTLD: posttransplant lymphoproliferative disorders; DM: diabetes mellitus; CMV: cytomegalovirus; TBI: total body irradiation.
Factors with statistical significance () upon univariate analysis were included in multivariate analysis.